-+ 0.00%
-+ 0.00%
-+ 0.00%
Novo Nordisk's US stock fell more than 7% in the premarket, and its 2030 strategic target fell short of expectations.
Share
Listen to the news
Novo Nordisk's US stock fell more than 7% in the premarket, and its 2030 strategic target fell short of expectations.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending